Press ReleaseNeurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
SAN DIEGO, June 16, 2010 /PRNewswire via COMTEX/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will host a conference call to report on the global agreement with Abbott for the exclusive worldwide development and commercialization of elagolix and the next-generation GnRH antagonists.
The live conference call and webcast will be held on Wednesday, June 16, 2010 at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time). Participants can access the live conference call by dialing 1-800-862-9098 (US) or 785-424-1051 (International) using the conference ID: 7NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com. If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-839-3012 (US) or 402-220-7232 (International) using the conference ID: 7NBIX. The call will be archived for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.